Sundrug Co.,Ltd. Logo

Sundrug Co.,Ltd.

9989.T

(3.2)
Stock Price

3.752,00 JPY

7.12% ROA

11.83% ROE

16.1x PER

Market Cap.

475.290.802.528,00 JPY

13.79% DER

3% Yield

3.86% NPM

Sundrug Co.,Ltd. Stock Analysis

Sundrug Co.,Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Sundrug Co.,Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Assets Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

3 Dividend Growth

Investors can take confidence in the company's impressive track record of annual dividend growth over the last five years, showcasing a commitment to rewarding shareholders.

4 ROE

The stock's ROE falls within an average range (11.45%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (8.21%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

6 PBV

The stock's PBV ratio (2.26x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

7 Revenue Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

8 Net Profit Growth

With continuous net profit growth in the past three years, this company demonstrates a strong financial performance, making it an enticing investment opportunity.

9 Dividend

The company has consistently provided dividends over the past three years, indicating a reliable source of income for investors.

10 Buffet Intrinsic Value

The company's stock seems undervalued (114.846) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

11 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

Sundrug Co.,Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Sundrug Co.,Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Sundrug Co.,Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Sundrug Co.,Ltd. Revenue
Year Revenue Growth
2004 153.949.000.000
2005 177.507.000.000 13.27%
2006 197.768.000.000 10.24%
2007 218.133.000.000 9.34%
2008 232.532.000.000 6.19%
2009 284.112.000.000 18.15%
2010 360.655.000.000 21.22%
2011 386.836.000.000 6.77%
2012 407.401.000.000 5.05%
2013 447.819.000.000 9.03%
2014 445.818.000.000 -0.45%
2015 503.773.000.000 11.5%
2016 528.394.000.000 4.66%
2017 564.215.000.000 6.35%
2018 588.069.000.000 4.06%
2019 617.769.000.000 4.81%
2020 634.310.000.000 2.61%
2021 648.734.000.000 2.22%
2022 690.462.000.000 6.04%
2023 758.244.000.000 8.94%
2023 751.777.000.000 -0.86%
2024 778.260.000.000 3.4%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Sundrug Co.,Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2004 0
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Sundrug Co.,Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2004 11.000.000
2005 9.000.000 -22.22%
2006 9.000.000 0%
2007 303.000.000 97.03%
2008 179.000.000 -69.27%
2009 409.000.000 56.23%
2010 184.000.000 -122.28%
2011 318.000.000 42.14%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 11.000.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Sundrug Co.,Ltd. EBITDA
Year EBITDA Growth
2004 12.695.000.000
2005 14.286.000.000 11.14%
2006 14.943.000.000 4.4%
2007 31.331.000.000 52.31%
2008 34.046.000.000 7.97%
2009 40.187.000.000 15.28%
2010 49.249.000.000 18.4%
2011 55.508.000.000 11.28%
2012 30.611.000.000 -81.33%
2013 34.397.000.000 11.01%
2014 32.734.000.000 -5.08%
2015 40.242.000.000 18.66%
2016 41.850.000.000 3.84%
2017 44.587.000.000 6.14%
2018 44.048.000.000 -1.22%
2019 45.526.000.000 3.25%
2020 46.801.000.000 2.72%
2021 44.917.000.000 -4.19%
2022 50.239.000.000 10.59%
2023 43.428.000.000 -15.68%
2023 56.239.000.000 22.78%
2024 59.576.000.000 5.6%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Sundrug Co.,Ltd. Gross Profit
Year Gross Profit Growth
2004 33.907.000.000
2005 39.761.000.000 14.72%
2006 45.541.000.000 12.69%
2007 50.330.000.000 9.52%
2008 54.785.000.000 8.13%
2009 65.800.000.000 16.74%
2010 81.797.000.000 19.56%
2011 89.889.000.000 9%
2012 96.531.000.000 6.88%
2013 105.845.000.000 8.8%
2014 108.236.000.000 2.21%
2015 124.119.000.000 12.8%
2016 130.748.000.000 5.07%
2017 140.959.000.000 7.24%
2018 147.178.000.000 4.23%
2019 154.619.000.000 4.81%
2020 158.550.000.000 2.48%
2021 156.506.000.000 -1.31%
2022 171.946.000.000 8.98%
2023 190.920.000.000 9.94%
2023 189.320.000.000 -0.85%
2024 196.628.000.000 3.72%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Sundrug Co.,Ltd. Net Profit
Year Net Profit Growth
2004 6.625.000.000
2005 7.319.000.000 9.48%
2006 7.492.000.000 2.31%
2007 7.706.000.000 2.78%
2008 8.918.000.000 13.59%
2009 9.440.000.000 5.53%
2010 10.871.000.000 13.16%
2011 12.580.000.000 13.59%
2012 14.955.000.000 15.88%
2013 15.754.000.000 5.07%
2014 16.362.000.000 3.72%
2015 21.569.000.000 24.14%
2016 23.312.000.000 7.48%
2017 24.829.000.000 6.11%
2018 23.933.000.000 -3.74%
2019 23.692.000.000 -1.02%
2020 25.329.000.000 6.46%
2021 23.853.000.000 -6.19%
2022 25.703.000.000 7.2%
2023 28.616.000.000 10.18%
2023 29.126.000.000 1.75%
2024 29.160.000.000 0.12%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Sundrug Co.,Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2004 103
2005 115 9.65%
2006 59 -93.22%
2007 61 3.28%
2008 71 12.86%
2009 75 5.41%
2010 86 13.95%
2011 100 13.13%
2012 119 16.1%
2013 125 4.84%
2014 133 6.77%
2015 178 25.28%
2016 197 9.64%
2017 212 7.08%
2018 205 -3.92%
2019 203 -0.99%
2020 217 6.48%
2021 204 -5.88%
2022 220 6.85%
2023 0 0%
2023 249 100%
2024 249 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Sundrug Co.,Ltd. Free Cashflow
Year Free Cashflow Growth
2004 5.509.000.000
2005 2.738.000.000 -101.21%
2006 5.693.000.000 51.91%
2007 7.896.000.000 27.9%
2008 8.144.000.000 3.05%
2009 5.852.000.000 -39.17%
2010 12.699.000.000 53.92%
2011 9.964.000.000 -27.45%
2012 14.190.000.000 29.78%
2013 24.322.000.000 41.66%
2014 2.346.000.000 -936.74%
2015 24.454.000.000 90.41%
2016 16.864.000.000 -45.01%
2017 23.687.000.000 28.8%
2018 19.897.000.000 -19.05%
2019 20.971.000.000 5.12%
2020 15.286.000.000 -37.19%
2021 11.893.000.000 -28.53%
2022 11.267.000.000 -5.56%
2023 571.000.000 -1873.2%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Sundrug Co.,Ltd. Operating Cashflow
Year Operating Cashflow Growth
2004 8.057.000.000
2005 5.971.000.000 -34.94%
2006 9.313.000.000 35.89%
2007 10.464.000.000 11%
2008 10.227.000.000 -2.32%
2009 9.756.000.000 -4.83%
2010 18.046.000.000 45.94%
2011 17.021.000.000 -6.02%
2012 23.044.000.000 26.14%
2013 32.321.000.000 28.7%
2014 12.829.000.000 -151.94%
2015 33.575.000.000 61.79%
2016 28.226.000.000 -18.95%
2017 36.148.000.000 21.92%
2018 31.091.000.000 -16.27%
2019 32.274.000.000 3.67%
2020 31.761.000.000 -1.62%
2021 31.682.000.000 -0.25%
2022 37.380.000.000 15.24%
2023 8.886.500.000 -320.64%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Sundrug Co.,Ltd. Capital Expenditure
Year Capital Expenditure Growth
2004 2.548.000.000
2005 3.233.000.000 21.19%
2006 3.620.000.000 10.69%
2007 2.568.000.000 -40.97%
2008 2.083.000.000 -23.28%
2009 3.904.000.000 46.64%
2010 5.347.000.000 26.99%
2011 7.057.000.000 24.23%
2012 8.854.000.000 20.3%
2013 7.999.000.000 -10.69%
2014 10.483.000.000 23.7%
2015 9.121.000.000 -14.93%
2016 11.362.000.000 19.72%
2017 12.461.000.000 8.82%
2018 11.194.000.000 -11.32%
2019 11.303.000.000 0.96%
2020 16.475.000.000 31.39%
2021 19.789.000.000 16.75%
2022 26.113.000.000 24.22%
2023 8.315.500.000 -214.03%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Sundrug Co.,Ltd. Equity
Year Equity Growth
2004 36.903.000.000
2005 42.745.000.000 13.67%
2006 48.857.000.000 12.51%
2007 54.656.000.000 10.61%
2008 61.770.000.000 11.52%
2009 69.343.000.000 10.92%
2010 78.242.000.000 11.37%
2011 88.560.000.000 11.65%
2012 100.771.000.000 12.12%
2013 113.205.000.000 10.98%
2014 115.987.000.000 2.4%
2015 133.285.000.000 12.98%
2016 136.335.000.000 2.24%
2017 154.828.000.000 11.94%
2018 171.055.000.000 9.49%
2019 186.821.000.000 8.44%
2020 205.155.000.000 8.94%
2021 220.592.000.000 7%
2022 236.327.000.000 6.66%
2023 244.668.000.000 3.41%
2023 253.090.000.000 3.33%
2024 253.746.000.000 0.26%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Sundrug Co.,Ltd. Assets
Year Assets Growth
2004 63.112.000.000
2005 69.531.000.000 9.23%
2006 79.251.000.000 12.26%
2007 87.623.000.000 9.55%
2008 98.997.000.000 11.49%
2009 130.253.000.000 24%
2010 140.009.000.000 6.97%
2011 153.423.000.000 8.74%
2012 168.073.000.000 8.72%
2013 192.167.000.000 12.54%
2014 189.688.000.000 -1.31%
2015 217.032.000.000 12.6%
2016 220.938.000.000 1.77%
2017 246.619.000.000 10.41%
2018 262.195.000.000 5.94%
2019 284.276.000.000 7.77%
2020 308.528.000.000 7.86%
2021 325.768.000.000 5.29%
2022 360.672.000.000 9.68%
2023 369.884.000.000 2.49%
2023 421.305.000.000 12.21%
2024 416.183.000.000 -1.23%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Sundrug Co.,Ltd. Liabilities
Year Liabilities Growth
2004 26.209.000.000
2005 26.786.000.000 2.15%
2006 30.394.000.000 11.87%
2007 32.967.000.000 7.8%
2008 37.227.000.000 11.44%
2009 60.910.000.000 38.88%
2010 61.767.000.000 1.39%
2011 64.863.000.000 4.77%
2012 67.302.000.000 3.62%
2013 78.962.000.000 14.77%
2014 73.701.000.000 -7.14%
2015 83.747.000.000 12%
2016 84.603.000.000 1.01%
2017 91.791.000.000 7.83%
2018 91.140.000.000 -0.71%
2019 97.455.000.000 6.48%
2020 103.373.000.000 5.72%
2021 105.176.000.000 1.71%
2022 124.345.000.000 15.42%
2023 125.216.000.000 0.7%
2023 168.213.000.000 25.56%
2024 162.435.000.000 -3.56%

Sundrug Co.,Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
6534.29
Net Income per Share
252.38
Price to Earning Ratio
16.1x
Price To Sales Ratio
0.62x
POCF Ratio
15.59
PFCF Ratio
21.43
Price to Book Ratio
1.87
EV to Sales
0.59
EV Over EBITDA
8.83
EV to Operating CashFlow
14.69
EV to FreeCashFlow
20.2
Earnings Yield
0.06
FreeCashFlow Yield
0.05
Market Cap
475,29 Bil.
Enterprise Value
447,94 Bil.
Graham Number
3510.05
Graham NetNet
-286.64

Income Statement Metrics

Net Income per Share
252.38
Income Quality
1.05
ROE
0.12
Return On Assets
0.07
Return On Capital Employed
0.14
Net Income per EBT
0.71
EBT Per Ebit
0.99
Ebit per Revenue
0.05
Effective Tax Rate
0.29

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.25
Operating Profit Margin
0.05
Pretax Profit Margin
0.05
Net Profit Margin
0.04

Dividends

Dividend Yield
0.03
Dividend Yield %
3
Payout Ratio
0.11
Dividend Per Share
122

Operating Metrics

Operating Cashflow per Share
260.71
Free CashFlow per Share
189.61
Capex to Operating CashFlow
0.27
Capex to Revenue
0.01
Capex to Depreciation
0.56
Return on Invested Capital
0.1
Return on Tangible Assets
0.07
Days Sales Outstanding
12.35
Days Payables Outstanding
49.67
Days of Inventory on Hand
60.31
Receivables Turnover
29.55
Payables Turnover
7.35
Inventory Turnover
6.05
Capex per Share
71.1

Balance Sheet

Cash per Share
533,13
Book Value per Share
2.169,68
Tangible Book Value per Share
2156.63
Shareholders Equity per Share
2169.67
Interest Debt per Share
299.65
Debt to Equity
0.14
Debt to Assets
0.08
Net Debt to EBITDA
-0.54
Current Ratio
1.7
Tangible Asset Value
252,22 Bil.
Net Current Asset Value
39,56 Bil.
Invested Capital
208291000000
Working Capital
83,12 Bil.
Intangibles to Total Assets
0
Average Receivables
34,25 Bil.
Average Payables
77,53 Bil.
Average Inventory
92815500000
Debt to Market Cap
0.07

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Sundrug Co.,Ltd. Dividends
Year Dividends Growth
2001 30
2002 25 -20%
2003 30 16.67%
2004 15 -100%
2005 45 66.67%
2006 50 10%
2007 24 -108.33%
2008 28 14.29%
2009 30 6.67%
2010 31 3.23%
2011 36 13.89%
2012 44 18.18%
2013 52 15.38%
2014 60 13.33%
2015 70 14.29%
2016 90 22.22%
2017 82 -9.76%
2018 66 -24.24%
2019 67 1.49%
2020 69 2.9%
2021 70 1.43%
2022 85 17.65%
2023 107 20.56%
2024 122 12.3%
2025 0 0%

Sundrug Co.,Ltd. Profile

About Sundrug Co.,Ltd.

Sundrug Co.,Ltd. operates and manages drug stores and dispensing pharmacies in Japan. It also operates discount stores that offers food, cosmetics, home appliances, clothing, car supplies, sports and goods, alcoholic beverages, and pharmaceutical products, as well as fresh food, kerosene, etc. The company was founded in 1957 and is headquartered in Fuchu, Japan.

CEO
Mr. Hiroshi Sadakata
Employee
6.662
Address
1-38-1, Wakamatsucho
Fuchu, 183-0005

Sundrug Co.,Ltd. Executives & BODs

Sundrug Co.,Ltd. Executives & BODs
# Name Age
1 Mr. Kazuhiro Tsuruta
Chief of Office of President & GM of Sales Department
70
2 Mr. Hiroshi Sadakata
Chief Executive Officer, President & Representative Director
70
3 Mr. Yoshimitsu Sakai
GM of Store Development Department & Director
70

Sundrug Co.,Ltd. Competitors